Goldman says this biotech could become a global cell therapy leader, has nearly 40% upside

The firm initiated coverage of the stock with a buy rating.

Related Keywords

Ziyi Chen ,Goldman Sachs ,European Union ,Johnson ,Legend Biotech ,Analyst Ziyi Chen ,Goldman Sachs Bdc Inc ,Environment ,Legend Biotech Corp ,Stock Markets ,Investment Strategy ,Johnson Amp ,Business News ,